Therapy assessment in prostate cancer using choline and PSMA PET/CT.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28540419.
- Also identified by DOI 10.1007/s00259-017-3723-3.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
While PET with non-FDG tracers (mainly choline and Ga-PSMA) has commonly been used for restaging in men with biochemically recurrent prostate cancer, as well as for primary staging, it is only recently that a few preliminary studies have addressed the possible use of PET for monitoring the response to systemic therapy of metastatic disease, especially innovative treatments such as abiraterone and enzalutamide. This article aims to evaluate the role of PET imaging with different non-FDG radiotracers for assessment of therapy in advanced prostate cancer patients.
Medical subject headings
- Antigens, Surface
- Choline
- Glutamate Carboxypeptidase II
- Positron Emission Tomography Computed Tomography
- Prostatic Neoplasms